Is Zomedica Pharmaceuticals Stock a Good Investment?
Zomedica Pharmaceuticals Investment Advice | ZOM |
Recommendations are not available for this entity. Please try other suggestions below
We are unable to locate Zomedica Pharmaceuticals Corp Advice at this time.
If you believe the indicator you are trying to look up is valid, please let us know, and we will check it out. Check all delisted instruments across multiple markets.| Symbol | ZOM |
| Name | Zomedica Pharmaceuticals Corp |
| Type | Stock |
| Country | United States |
| Exchange | NYSE MKT |
Other Suggestions
| Z | Zillow Group Class | ETF |
| ZD | Ziff Davis | Company |
| ZIONP | Zions Bancorporation National | Company |
| ZTR | Virtus Global Dividend | Fund |
| ZB | ZB | Cryptocurrency |
| ZCUSX | Corn Futures | Commodity |
| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria | |
| HMY | Harmony Gold Mining | |
| FSM | Fortuna Silver Mines |
Examine Zomedica Pharmaceuticals Stock
Researching Zomedica Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has Price to Book (P/B) ratio of 0.28. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zomedica Pharmaceuticals recorded a loss per share of 0.06. The entity had not issued any dividends in recent years.
To determine if Zomedica Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Zomedica Pharmaceuticals' research are outlined below:
| Zomedica Pharmaceuticals generated a negative expected return over the last 90 days | |
| Zomedica Pharmaceuticals has high historical volatility and very poor performance | |
| Zomedica Pharmaceuticals has some characteristics of a very speculative penny stock | |
| The company reported the last year's revenue of 27.29 M. Reported Net Loss for the year was (46.98 M) with profit before taxes, overhead, and interest of 13.65 M. | |
| Zomedica Pharmaceuticals Corp has about 27.4 M in cash with (23.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Zomedica Pharmaceuticals has a frail financial position based on the latest SEC disclosures |
Zomedica Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Zomedica Pharmaceuticals Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zomedica Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Zomedica Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 147.6 M.Zomedica Pharmaceuticals' profitablity analysis
The company has Net Profit Margin of (2.15) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (1.47) %, which entails that for every $100 of revenue, it lost $1.47.Determining Zomedica Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Zomedica Pharmaceuticals is a good buy. For example, gross profit margin measures Zomedica Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Zomedica Pharmaceuticals' profitability and make more informed investment decisions.
Basic technical analysis of Zomedica Stock
As of the 28th of March, Zomedica Pharmaceuticals maintains the Standard Deviation of 11.64, market risk adjusted performance of (0.26), and Mean Deviation of 5.94. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zomedica Pharmaceuticals Corp, as well as the relationship between them. Please check out Zomedica Pharmaceuticals market risk adjusted performance and treynor ratio to decide if Zomedica Pharmaceuticals is priced fairly, providing market reflects its latest price of 0.058 per share. As Zomedica Pharmaceuticals appears to be a penny stock we also urge to confirm its jensen alpha numbers.Zomedica Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zomedica Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zomedica Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zomedica Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zomedica Pharmaceuticals' Outstanding Corporate Bonds
Zomedica Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zomedica Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zomedica bonds can be classified according to their maturity, which is the date when Zomedica Pharmaceuticals Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Zomedica Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Zomedica Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 5.94 | |||
| Coefficient Of Variation | (2,621) | |||
| Standard Deviation | 11.64 | |||
| Variance | 135.57 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.36) | |||
| Total Risk Alpha | 0.2759 | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 67.33 | |||
| Value At Risk | (11.36) | |||
| Potential Upside | 16.67 | |||
| Skewness | (0.23) | |||
| Kurtosis | 8.24 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.26) | |||
| Mean Deviation | 5.94 | |||
| Coefficient Of Variation | (2,621) | |||
| Standard Deviation | 11.64 | |||
| Variance | 135.57 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.36) | |||
| Total Risk Alpha | 0.2759 | |||
| Treynor Ratio | (0.27) | |||
| Maximum Drawdown | 67.33 | |||
| Value At Risk | (11.36) | |||
| Potential Upside | 16.67 | |||
| Skewness | (0.23) | |||
| Kurtosis | 8.24 |
Consider Zomedica Pharmaceuticals' intraday indicators
Zomedica Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Zomedica Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Zomedica Pharmaceuticals time-series forecasting models is one of many Zomedica Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Zomedica Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Zomedica Stock media impact
Far too much social signal, news, headlines, and media speculation about Zomedica Pharmaceuticals that are available to investors today. That information is available publicly through Zomedica media outlets and privately through word of mouth or via Zomedica internal channels. However, regardless of the origin, that massive amount of Zomedica data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Zomedica Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Zomedica Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Zomedica Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Zomedica Pharmaceuticals alpha.
Zomedica Pharmaceuticals Corporate Directors
| Thomas Robitaille | Independent Director | Profile | |
| Johnny Powers | Independent Director | Profile | |
| Jane Eagleson | Independent Director | Profile | |
| Angy Guerrant | Director of Portfolio Management | Profile |
Already Invested in Zomedica Pharmaceuticals Corp?
The danger of trading Zomedica Pharmaceuticals Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zomedica Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zomedica Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zomedica Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Zomedica Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.